Soligenix Reports FY EPS of -$2.14, Beats Estimates
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy SNGX?
Source: seekingalpha
- Fiscal Year Performance: Soligenix reported a FY GAAP EPS of -$2.14, beating market expectations by $0.01, indicating a slight improvement in financial performance that may bolster investor confidence.
- Historical Financial Data: Historical data shows that Soligenix's financial performance has fluctuated over the years; although the current EPS remains negative, the better-than-expected result could lay the groundwork for future profitability.
- Market Reaction Analysis: Investors reacted positively to Soligenix's earnings report, which may drive the stock price up in the short term, reflecting market optimism regarding the company's future prospects.
- Quant Rating Attention: Seeking Alpha's Quant Rating on Soligenix highlights market interest in its financial health, prompting investors to closely monitor upcoming financial reports and market developments.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SNGX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SNGX
Wall Street analysts forecast SNGX stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.110
Low
10.00
Averages
10.00
High
10.00
Current: 1.110
Low
10.00
Averages
10.00
High
10.00
About SNGX
Soligenix, Inc. is a late-stage biopharmaceutical company, which is focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. The Company’s segments include Specialized Biotherapeutics, and Public Health Solutions. Its Specialized BioTherapeutics business segment is engaged in developing and focused on the commercialization of HyBryte (a proposed name of SGX301), a novel photodynamic therapy (PDT), utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). Its Public Health Solutions segment includes development programs for RiVax, its ricin toxin vaccine candidate and SGX943, its therapeutic candidate for antibiotic-resistant and emerging infectious diseases and its vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax, its vaccine candidate for the prevention of COVID-19 (caused by SARS-CoV-2).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Soligenix Reports 2025 Financial Results and Upcoming Milestones
- Clinical Trial Progress: Soligenix plans to conduct an interim analysis of the HyBryte™ clinical trial in Q2 2026, with top-line results expected in H2 2026, which will provide critical data for the treatment of early-stage cutaneous T-cell lymphoma, thereby enhancing the company's competitive position in the rare disease market.
- Financial Status: As of December 31, 2025, Soligenix reported a cash balance of approximately $7.9 million; despite having no revenue, the company has sufficient funds to support operations into Q4 2026, reflecting its disciplined capital management strategy.
- Increased R&D Investment: Research and development expenses rose to $7.5 million in 2025 from $5.2 million in 2024, primarily driven by costs associated with the Phase 2 study for Behçet's Disease and the ongoing confirmatory Phase 3 study for CTCL, indicating the company's commitment to investing in rare disease treatments.
- Regulatory Progress: The company received orphan drug designation for dusquetide from the European Commission in March 2026, which not only enhances the market potential for SGX945 but may also pave the way for future financing and partnership opportunities.
See More
Soligenix Reports FY EPS of -$2.14, Beats Estimates
- Fiscal Year Performance: Soligenix reported a FY GAAP EPS of -$2.14, beating market expectations by $0.01, indicating a slight improvement in financial performance that may bolster investor confidence.
- Historical Financial Data: Historical data shows that Soligenix's financial performance has fluctuated over the years; although the current EPS remains negative, the better-than-expected result could lay the groundwork for future profitability.
- Market Reaction Analysis: Investors reacted positively to Soligenix's earnings report, which may drive the stock price up in the short term, reflecting market optimism regarding the company's future prospects.
- Quant Rating Attention: Seeking Alpha's Quant Rating on Soligenix highlights market interest in its financial health, prompting investors to closely monitor upcoming financial reports and market developments.
See More
Soligenix Reports 2025 Financial Results and Upcoming Milestones
- Clinical Trial Progress: Soligenix plans to conduct an interim analysis of the HyBryte™ clinical trial in Q2 2026, with top-line results expected in H2 2026, which will provide critical data to support the company's market potential in treating early-stage cutaneous T-cell lymphoma.
- Deteriorating Financials: As of December 31, 2025, Soligenix reported a net loss of $11.1 million, or $2.14 per share, an increase from $8.3 million and $4.98 per share in the previous year, primarily due to rising R&D costs and decreased other income, indicating pressure on the company's financial management.
- Increased R&D Spending: Research and development expenses rose to $7.5 million in 2025 from $5.2 million in 2024, reflecting heightened investment in studies for Behçet's Disease and CTCL, which may impact short-term financial performance but is essential for long-term product development.
- Cash Flow Status: Soligenix ended 2025 with approximately $7.9 million in cash, which provides an operational runway into Q4 2026; however, the company is exploring various strategic options, including partnerships, mergers, and financing, to advance its late-stage pipeline.
See More
Soligenix Receives EU Orphan Drug Designation for SGX945
- Orphan Drug Designation: Soligenix's SGX945 has received orphan drug designation from the European Commission for treating Behçet's Disease, based on positive evaluations of its clinical trial results by the EMA, marking a significant advancement in addressing unmet medical needs.
- Market Exclusivity: Following the orphan drug designation, SGX945 will enjoy a 10-year period of market exclusivity in the EU, which will enhance the company's competitive edge and attract more investor interest in its product development.
- Clinical Trial Results: In a Phase 2a clinical trial involving 8 patients with Behçet's Disease, SGX945 demonstrated a 40% improvement in efficacy compared to a 37% improvement in the placebo group, indicating its potential in treating difficult-to-manage oral ulcers.
- Intellectual Property Protection: Soligenix holds a strong intellectual property position in its IDR technology platform, including patents for the composition of dusquetide and related analogs, which will further strengthen its market position in the biopharmaceutical sector.
See More
Soligenix Receives EU Orphan Drug Designation for SGX945
- Orphan Drug Designation: Soligenix's SGX945 has received orphan drug designation from the European Commission for treating Behçet's Disease, marking a significant advancement in addressing unmet medical needs and is expected to enhance the company's market competitiveness.
- Clinical Trial Results: In the Phase 2a clinical trial, SGX945 demonstrated biological efficacy and safety, with the treatment group showing a 40% improvement in oral ulcers compared to the placebo group, laying a solid foundation for future market approval.
- Market Potential: With approximately 1 million people affected by Behçet's Disease globally, the successful development of SGX945 could provide new treatment options for these patients, potentially significantly increasing the company's revenue prospects.
- Intellectual Property Advantage: Soligenix holds a strong intellectual property position in its IDR technology platform, and the orphan drug and fast track designations for SGX945 will provide legal protection and market exclusivity for its future commercialization efforts.
See More
Soligenix Highlights Positive Results for HyBryte™ in CTCL Treatment
- Clinical Trial Results: Soligenix is presenting positive findings for HyBryte™ in treating cutaneous T-cell lymphoma (CTCL) at the upcoming US Cutaneous Lymphoma Consortium Workshop, indicating significant clinical benefits in long-term treatment that could reshape CTCL therapy.
- Comparative Study Advantage: A study led by Dr. Brian Poligone shows that HyBryte™ demonstrates superior relative efficacy and tolerability compared to Valchlor® (mechlorethamine) in CTCL treatment, potentially offering patients a safer treatment option with reduced side effects.
- FDA Funding Support: The FDA awarded a $2.6 million Orphan Products Development grant to support the expanded treatment study of HyBryte™ in early-stage CTCL patients, further validating its effectiveness in home use settings and highlighting regulatory interest in the therapy.
- Follow-Up Research Plans: Soligenix is conducting a second Phase 3 trial, FLASH2, expected to enroll approximately 80 early-stage CTCL patients with an 18-week continuous treatment design, aimed at further validating HyBryte™'s efficacy and advancing its path to market approval.
See More
Soligenix Reports 2025 Financial Results and Upcoming Milestones
- Clinical Trial Progress: Soligenix plans to conduct an interim analysis of the HyBryte™ clinical trial in Q2 2026, with top-line results expected in H2 2026, which will provide critical data for the treatment of early-stage cutaneous T-cell lymphoma, thereby enhancing the company's competitive position in the rare disease market.
- Financial Status: As of December 31, 2025, Soligenix reported a cash balance of approximately $7.9 million; despite having no revenue, the company has sufficient funds to support operations into Q4 2026, reflecting its disciplined capital management strategy.
- Increased R&D Investment: Research and development expenses rose to $7.5 million in 2025 from $5.2 million in 2024, primarily driven by costs associated with the Phase 2 study for Behçet's Disease and the ongoing confirmatory Phase 3 study for CTCL, indicating the company's commitment to investing in rare disease treatments.
- Regulatory Progress: The company received orphan drug designation for dusquetide from the European Commission in March 2026, which not only enhances the market potential for SGX945 but may also pave the way for future financing and partnership opportunities.
See More
Soligenix Reports FY EPS of -$2.14, Beats Estimates
- Fiscal Year Performance: Soligenix reported a FY GAAP EPS of -$2.14, beating market expectations by $0.01, indicating a slight improvement in financial performance that may bolster investor confidence.
- Historical Financial Data: Historical data shows that Soligenix's financial performance has fluctuated over the years; although the current EPS remains negative, the better-than-expected result could lay the groundwork for future profitability.
- Market Reaction Analysis: Investors reacted positively to Soligenix's earnings report, which may drive the stock price up in the short term, reflecting market optimism regarding the company's future prospects.
- Quant Rating Attention: Seeking Alpha's Quant Rating on Soligenix highlights market interest in its financial health, prompting investors to closely monitor upcoming financial reports and market developments.
See More
Soligenix Reports 2025 Financial Results and Upcoming Milestones
- Clinical Trial Progress: Soligenix plans to conduct an interim analysis of the HyBryte™ clinical trial in Q2 2026, with top-line results expected in H2 2026, which will provide critical data to support the company's market potential in treating early-stage cutaneous T-cell lymphoma.
- Deteriorating Financials: As of December 31, 2025, Soligenix reported a net loss of $11.1 million, or $2.14 per share, an increase from $8.3 million and $4.98 per share in the previous year, primarily due to rising R&D costs and decreased other income, indicating pressure on the company's financial management.
- Increased R&D Spending: Research and development expenses rose to $7.5 million in 2025 from $5.2 million in 2024, reflecting heightened investment in studies for Behçet's Disease and CTCL, which may impact short-term financial performance but is essential for long-term product development.
- Cash Flow Status: Soligenix ended 2025 with approximately $7.9 million in cash, which provides an operational runway into Q4 2026; however, the company is exploring various strategic options, including partnerships, mergers, and financing, to advance its late-stage pipeline.
See More
Soligenix Receives EU Orphan Drug Designation for SGX945
- Orphan Drug Designation: Soligenix's SGX945 has received orphan drug designation from the European Commission for treating Behçet's Disease, based on positive evaluations of its clinical trial results by the EMA, marking a significant advancement in addressing unmet medical needs.
- Market Exclusivity: Following the orphan drug designation, SGX945 will enjoy a 10-year period of market exclusivity in the EU, which will enhance the company's competitive edge and attract more investor interest in its product development.
- Clinical Trial Results: In a Phase 2a clinical trial involving 8 patients with Behçet's Disease, SGX945 demonstrated a 40% improvement in efficacy compared to a 37% improvement in the placebo group, indicating its potential in treating difficult-to-manage oral ulcers.
- Intellectual Property Protection: Soligenix holds a strong intellectual property position in its IDR technology platform, including patents for the composition of dusquetide and related analogs, which will further strengthen its market position in the biopharmaceutical sector.
See More
Soligenix Receives EU Orphan Drug Designation for SGX945
- Orphan Drug Designation: Soligenix's SGX945 has received orphan drug designation from the European Commission for treating Behçet's Disease, marking a significant advancement in addressing unmet medical needs and is expected to enhance the company's market competitiveness.
- Clinical Trial Results: In the Phase 2a clinical trial, SGX945 demonstrated biological efficacy and safety, with the treatment group showing a 40% improvement in oral ulcers compared to the placebo group, laying a solid foundation for future market approval.
- Market Potential: With approximately 1 million people affected by Behçet's Disease globally, the successful development of SGX945 could provide new treatment options for these patients, potentially significantly increasing the company's revenue prospects.
- Intellectual Property Advantage: Soligenix holds a strong intellectual property position in its IDR technology platform, and the orphan drug and fast track designations for SGX945 will provide legal protection and market exclusivity for its future commercialization efforts.
See More
Soligenix Highlights Positive Results for HyBryte™ in CTCL Treatment
- Clinical Trial Results: Soligenix is presenting positive findings for HyBryte™ in treating cutaneous T-cell lymphoma (CTCL) at the upcoming US Cutaneous Lymphoma Consortium Workshop, indicating significant clinical benefits in long-term treatment that could reshape CTCL therapy.
- Comparative Study Advantage: A study led by Dr. Brian Poligone shows that HyBryte™ demonstrates superior relative efficacy and tolerability compared to Valchlor® (mechlorethamine) in CTCL treatment, potentially offering patients a safer treatment option with reduced side effects.
- FDA Funding Support: The FDA awarded a $2.6 million Orphan Products Development grant to support the expanded treatment study of HyBryte™ in early-stage CTCL patients, further validating its effectiveness in home use settings and highlighting regulatory interest in the therapy.
- Follow-Up Research Plans: Soligenix is conducting a second Phase 3 trial, FLASH2, expected to enroll approximately 80 early-stage CTCL patients with an 18-week continuous treatment design, aimed at further validating HyBryte™'s efficacy and advancing its path to market approval.
See More
